Autophagy Inhibition in BRAF-Driven Cancers.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed, 28 citations in OpenAlex.

1. Variations in Autophagy-Related GenesCancers · 2026
   Article
2. Autophagy-Circulating Tumor DNA Axis in Molecular Cancer Research: Emerging Mechanisms, Therapeutic Targeting, and Translational Opportunities.International journal of molecular sciences · 2026
   Review
3. Resveratrol as a Dual MAPK/STAT3 Inhibitor in Glioblastoma: Mutation-Dependent Therapeutic Efficacy.Life (Basel, Switzerland) · 2026
   Article
4. Autophagy in thyroid cancer: stage-dependent switch, mutation-specific regulation, and therapeutic targeting.Oncology reviews · 2026
   Review
5. Pathway-Specific Therapeutic Modulation of Melanoma: Small-Molecule Inhibition of BRAF-MEK and KIT Signaling in Contemporary Precision Oncology with a Special Focus on Vemurafenib, Trametinib, and Imatinib.Journal of clinical medicine · 2025
   Review
6. Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis.Journal of clinical medicine · 2025
   Article
7. Matrine and Its Derivatives: Multi-Pathway Regulation in Cancer Therapy.Cancer management and research · 2025
   Review
8. Drug repurposing candidates for amyotrophic lateral sclerosis using common and rare genetic variants.Brain communications · 2025
   Article
9. Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations.Innovation (Cambridge (Mass.)) · 2024
   Review
10. Selective Termination of Autophagy-Dependent Cancers.Cells · 2024
    Review
11. Simulating BRAFV600E-MEK-ERK signalling dynamics in response to vertical inhibition treatment strategies.NPJ systems biology and applications · 2024
    Article
12. Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.Signal transduction and targeted therapy · 2023
    Review
13. A new glance at autophagolysosomal-dependent or -independent function of transcriptional factor EB in human cancer.Acta pharmacologica Sinica · 2023
    Review
14. Autophagy in BRAF-mutant cutaneous melanoma: recent advances and therapeutic perspective.Cell death discovery · 2023
    Review
15. Recent advances in targeting autophagy in cancer.Trends in pharmacological sciences · 2023
    Review
16. Advances in Molecular Pathophysiology and Targeted Therapy for Cushing's Disease.Cancers · 2023
    Review
17. DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicity.The Journal of experimental medicine · 2022
    Article
18. Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.International journal of molecular sciences · 2022
    Article
19. Autophagy: Guardian of Skin Barrier.Biomedicines · 2022
    Review
20. Functionalization of Nanomaterials for Skin Cancer Theranostics.Frontiers in bioengineering and biotechnology · 2022
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as